MX2020008116A - Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). - Google Patents
Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).Info
- Publication number
- MX2020008116A MX2020008116A MX2020008116A MX2020008116A MX2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A
- Authority
- MX
- Mexico
- Prior art keywords
- ghrelin
- goat
- heterocyclyl
- inhibitors
- acyl transferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, en donde las variables X, R1, n, p y q se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18154828 | 2018-02-02 | ||
PCT/EP2019/051993 WO2019149659A1 (en) | 2018-02-02 | 2019-01-28 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008116A true MX2020008116A (es) | 2020-09-25 |
Family
ID=61157053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008116A MX2020008116A (es) | 2018-02-02 | 2019-01-28 | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
Country Status (21)
Country | Link |
---|---|
US (1) | US11319310B2 (es) |
EP (1) | EP3746450B1 (es) |
JP (1) | JP7150032B2 (es) |
KR (1) | KR20200118124A (es) |
CN (1) | CN111655699B (es) |
AU (1) | AU2019215709A1 (es) |
BR (1) | BR112020014320A2 (es) |
CA (1) | CA3087827A1 (es) |
CL (1) | CL2020001908A1 (es) |
CO (1) | CO2020009179A2 (es) |
CR (1) | CR20200331A (es) |
EA (1) | EA202091804A1 (es) |
EC (1) | ECSP20050791A (es) |
IL (1) | IL276137A (es) |
JO (1) | JOP20200191A1 (es) |
MA (1) | MA53074A (es) |
MX (1) | MX2020008116A (es) |
PE (1) | PE20210175A1 (es) |
PH (1) | PH12020551169A1 (es) |
SG (1) | SG11202006300XA (es) |
WO (1) | WO2019149659A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037277B1 (ru) * | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
SG11202006302TA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
JP7225253B2 (ja) * | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
WO2021233884A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
EP2370459A1 (en) | 2008-12-15 | 2011-10-05 | Zealand Pharma A/S | Glucagon analogues |
CN102282166B (zh) | 2008-12-15 | 2015-04-01 | 西兰制药公司 | 胰高血糖素类似物 |
EA020520B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
SG177609A1 (en) | 2009-07-13 | 2012-02-28 | Zealand Pharma As | Acylated glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
MX2012014961A (es) | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Analogos de glucagon. |
EP2793931A2 (en) | 2011-12-23 | 2014-10-29 | Zealand Pharma A/S | Glucagon analogues |
US9238639B2 (en) | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
EP2863910B1 (en) | 2012-06-20 | 2020-03-11 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
US20170275249A1 (en) | 2014-09-17 | 2017-09-28 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
EP3250569B1 (en) | 2015-01-30 | 2019-01-09 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
EA037277B1 (ru) | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
-
2019
- 2019-01-28 PE PE2020001163A patent/PE20210175A1/es unknown
- 2019-01-28 AU AU2019215709A patent/AU2019215709A1/en not_active Abandoned
- 2019-01-28 CA CA3087827A patent/CA3087827A1/en not_active Abandoned
- 2019-01-28 MX MX2020008116A patent/MX2020008116A/es unknown
- 2019-01-28 WO PCT/EP2019/051993 patent/WO2019149659A1/en unknown
- 2019-01-28 KR KR1020207025418A patent/KR20200118124A/ko unknown
- 2019-01-28 BR BR112020014320-0A patent/BR112020014320A2/pt not_active Application Discontinuation
- 2019-01-28 EP EP19702085.2A patent/EP3746450B1/en active Active
- 2019-01-28 MA MA053074A patent/MA53074A/fr unknown
- 2019-01-28 US US16/966,489 patent/US11319310B2/en active Active
- 2019-01-28 CN CN201980010384.6A patent/CN111655699B/zh active Active
- 2019-01-28 CR CR20200331A patent/CR20200331A/es unknown
- 2019-01-28 JP JP2020541870A patent/JP7150032B2/ja active Active
- 2019-01-28 EA EA202091804A patent/EA202091804A1/ru unknown
- 2019-01-28 SG SG11202006300XA patent/SG11202006300XA/en unknown
- 2019-01-28 JO JOP/2020/0191A patent/JOP20200191A1/ar unknown
-
2020
- 2020-07-19 IL IL276137A patent/IL276137A/en unknown
- 2020-07-21 CL CL2020001908A patent/CL2020001908A1/es unknown
- 2020-07-24 CO CONC2020/0009179A patent/CO2020009179A2/es unknown
- 2020-07-31 PH PH12020551169A patent/PH12020551169A1/en unknown
- 2020-08-24 EC ECSENADI202050791A patent/ECSP20050791A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021512112A (ja) | 2021-05-13 |
JOP20200191A1 (ar) | 2020-07-29 |
MA53074A (fr) | 2021-05-12 |
CO2020009179A2 (es) | 2020-07-31 |
PH12020551169A1 (en) | 2021-05-31 |
CN111655699A (zh) | 2020-09-11 |
EA202091804A1 (ru) | 2020-12-24 |
EP3746450A1 (en) | 2020-12-09 |
IL276137A (en) | 2020-09-30 |
US11319310B2 (en) | 2022-05-03 |
ECSP20050791A (es) | 2020-09-30 |
SG11202006300XA (en) | 2020-07-29 |
BR112020014320A2 (pt) | 2020-12-08 |
CL2020001908A1 (es) | 2020-10-30 |
AU2019215709A1 (en) | 2020-07-16 |
EP3746450B1 (en) | 2022-03-16 |
JP7150032B2 (ja) | 2022-10-07 |
PE20210175A1 (es) | 2021-01-29 |
WO2019149659A1 (en) | 2019-08-08 |
KR20200118124A (ko) | 2020-10-14 |
CN111655699B (zh) | 2023-07-14 |
CR20200331A (es) | 2020-09-03 |
CA3087827A1 (en) | 2019-08-08 |
US20210040077A1 (en) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551170A1 (en) | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
MX2020008116A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
MY197064A (en) | Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
MX2020008053A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). | |
MX2020007383A (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47. | |
MX2021005311A (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock). | |
CR20200358A (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
EA033236B1 (ru) | Новые производные пиразола в качестве ингибиторов nik | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
PH12020550442A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
WO2018102256A8 (en) | Pyrrolidinone compounds | |
PH12021550258A1 (en) | Cdk8/19 inhibitors | |
MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
MX2020008706A (es) | Nuevos compuestos de opioides y sus usos. | |
TN2010000608A1 (en) | Heteroaryl derivatives as dgat1 inhibitors |